Patent US4880637A successfully refreshed from Google Patents.
US4880637A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions of catecholic butanes with zinc
Assignee: BLOCK/CHEMEX GP A NEW JERSEY GENERAL PARTNERSHIP
•
Filing: 1986-10-28
•
Granted: 1989-11-14
•
Expires: 2006-10-28
Abstract
Abstract The present invention provides new compositions comprising catecholic butanes and ionic zinc. The invention also relates to pharmacologically active compositions comprising said new compositions, which are useful in the treatment of benign, premalignant and malignant solid tumors, especially those of the skin. The ionic zinc may be in the form of a zinc salt, and the preferred catecholic butane is nordihydroguaiaretic acid.
Inventors
- 👤 Russell T. Jordan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 17:52
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/24; A61K33/30; A61P; A61P35/00
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
76 words
A pharmaceutical composition comprising at least 1 catecholic butane of the formula: ##STR3## wherein R 1 and R 2 are independently H, lower alkyl, or lower acyl; R 3 , R 4 , R 5 , R 6 , R 10 , R 11 , R 12 and R 13 are independently H or lower alkyl; R 7 , R 8 and R 9 are independently H, hydroxy, lower alkoxy or lower acyloxy; and ionic zinc.
Claim 2
Dependent Claim
76 words
A pharmaceutical composition comprising at least 1 catecholic butane of the formula: ##STR3## wherein R 1 and R 2 are independently H, lower alkyl, or lower acyl; R 3 , R 4 , R 5 , R 6 , R 10 , R 11 , R 12 and R 13 are independently H or lower alkyl; R 7 , R 8 and R 9 are independently H, hydroxy, lower alkoxy or lower acyloxy; and ionic zinc.
Claim 3
Dependent Claim
24 words
The compositions according to claim 1 wherein said ionic zinc is in the form of a zinc salt or chelate of said catecholic butane.
Claim 4
Dependent Claim
23 words
The compositions according to claim 1 wherein said ionic zinc is in the form of a zinc salt or a chelate of zinc.
Claim 5
Dependent Claim
24 words
The compositions according to claim 1 wherein the molar ratio of said catecholic butane to said ionic zinc is between about 10:1 and 1:20.
Claim 6
Dependent Claim
13 words
The composition according to claim 4 wherein the catecholic butane is nordihydroguaiaretic acid.
Claim 7
Dependent Claim
16 words
The composition according to claim 5 wherein the source of the ionic zinc is zinc chloride.
Claim 8
Dependent Claim
24 words
Pharmaceutical composition comprising a pharmaceutically acceptable carrier and the composition of claim 6 wherein said ionic zinc is derived from a pharmaceutically acceptable salt.
Claim 9
Dependent Claim
25 words
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the composition of claim 4 wherein said ionic zinc is derived from a pharmaceutically acceptable salt.
Claim 10
Dependent Claim
25 words
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the composition of claim 5 wherein said ionic zinc is derived from a pharmaceutically acceptable salt.
Claim 11
Dependent Claim
19 words
The composition according to claim 1 wherein said catecholic butane contains at least one lower alkyl ether derivative moiety.
Claim 12
Dependent Claim
19 words
The composition according to claim 1 wherein said catechol butane contains at least one lower acyl ether derivative moiety.
Claim 13
Dependent Claim
19 words
The composition according to claim 1, wherein the ionic zinc is a cation of a pharmaceutically acceptable soluble salt.
Claim 14
Dependent Claim
38 words
The composition according to claim 1, wherein lower alkyl is C 1 -C 6 alkyl, R 3 and R 4 are C 1 -C 3 alkyl and the lower acyl is a [C 1 -C 6 ] acyl.
Claim 15
Dependent Claim
34 words
The composition according to claim 1, wherein the catecholic butane is selected from the group consisting of 1,4-bis(3,4-dihydroxphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dihydroxyphenyl)butane; 1,4-bis(3,4-dimethoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-diethoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipropoxyphenyl)-2,3-dimethylbutane; 1-(3,4-dihydroxyphenyl)-4-(3,4,5-trihydroxyphenyl) butane; 1,4-bis(3,4-diacetoxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipropionyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dibutyroyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-divaleroyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dipivaloyloxyphenyl)-2,3-dimethylbutane; 1,4-bis(3,4-dineopentylcarboxylphenyl)-2,3-dimethylbutane; and 1-(3,4-dihydroxyphenyl)-4-phenylbutane; 1-(3,4-dihydroxyphenyl)-4-(2,5-dihydroxyphenyl) butane.
Claim 16
Dependent Claim
20 words
The pharmaceutical composition according to claim 1 wherein the catecholic butane is nordihydroguaiaretic acid in any of its racemic forms.
Claim 17
Dependent Claim
28 words
The composition according to claim 1 wherein the catecholic butane is selected from the group consisting of nordihydroguaiaretic acid tetrapivalate, nordihydroguaiaretic acid tetrapropionate and all optical configurations thereof.
Claim 18
Dependent Claim
14 words
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the composition of claim 1.
Claim 19
Independent Claim
102 words
A method for treating disorders of the skin, which comprises topically administering to a mammal in need of said treatment an effective amount of a composition comprising ionic zinc and at least one catecholic butane of the formula: ##STR4## wherein R 1 and R 2 are independently H, lower alkyl or lower acyl; R 3 , R 4 , R 5 , R 6 , R 10 , R 11 , R 12 and R 13 are independently H or lower alkyl; R 7 , R 8 and R 9 are independently H, hydroxy, lower alkoxy or lower acyloxy; and ionic zinc.
Claim 20
Independent Claim
102 words
A method for treating disorders of the skin, which comprises topically administering to a mammal in need of said treatment an effective amount of a composition comprising ionic zinc and at least one catecholic butane of the formula: ##STR4## wherein R 1 and R 2 are independently H, lower alkyl or lower acyl; R 3 , R 4 , R 5 , R 6 , R 10 , R 11 , R 12 and R 13 are independently H or lower alkyl; R 7 , R 8 and R 9 are independently H, hydroxy, lower alkoxy or lower acyloxy; and ionic zinc.
Claim 21
Dependent Claim
27 words
The method according to claim 18, wherein the catecholic butane is nordihydroguaiaretic acid, and the ionic zinc is a cation of a pharmaceutically acceptable water soluble salt.
Claim 22
Dependent Claim
36 words
The method according to claim 18 wherein the catecholic butane is selected from the group consisting of nordihydroguaiaretic acid in any of its racemic forms, nordihydroguaiaretic acid tetrapivalate, nordihydroguaiaretic acid tetrapropionate and all optical configurations thereof.
Claim 23
Dependent Claim
15 words
The method according to claim 18 wherein the disorder of the skin is actinic keratosis.
Claim 24
Dependent Claim
15 words
The method according to claim 18 wherein the disorder of the skin is a tumor.
Claim 25
Dependent Claim
20 words
The method according to claim 22, wherein 2-20 mg of composition are applied to each cm 2 of solid tumor.
Claim 26
Dependent Claim
14 words
The method according to claim 18 wherein the disorder of the skin is psoriasis.
Claim 27
Dependent Claim
34 words
The method according to claim 18 wherein the disorder of the skin is selected from the group consisting of tumors, actinic keratosis, acne, psoriasis, skin wounds warts, bacterial infections, fungal infections and viral infections.
References Cited (Backward Citations)
US4774229A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-11-13 | 1993-05-15 | 1993-11-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-11-13 | 1997-05-15 | 1997-11-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-11-13 | 2001-05-15 | 2001-11-14 | $7700.00 | Window Closed / Lapsed |